The latest issue of Cancer Today features articles on activity-based groups for cancer survivors, new treatment options for multiple myeloma, a drug that can boost chemotherapy’s effectiveness, and more. Read about the issue on the #AACRBlog: buff.ly/w8A603Y

Adolescents who develop colorectal cancer are often diagnosed at an advanced stage, 1 in 8 cancer cases globally is linked to infections, and more in the Week in Cancer News from Cancer Today magazine. buff.ly/DdRF2UZ

Register by October 27 to get the lowest rates for the AACR Special Conference on Advances in the Pathogenesis and Immune Therapies of Liver Cancer (December 6-8; Austin, Texas), chaired by Richard S. Finn, Josep M. Llovet, and Jessica Zucman-Rossi. Learn more:
buff.ly/QuyRLts
#AACRliver26

The findings suggest that all patients with cancer—not just patients under age 50—should be screened for inherited genetic variants associated with cancer. The research was conducted by Dr. Zsofia Stadler of @mskcancercenter.bsky.social and co-authors.

According to a study published in the journal Cancer Discovery from @aacrjournals.bsky.social, the typically used age cutoffs for germline genetic screening in patients with cancer may fail to detect the majority of inherited genetic risk factors for cancer. Read more: buff.ly/4fvAMqx

Breast cancer survivor Yvonne McLean Florence shares her experience in a clinical trial to help more Black people learn about opportunities to participate in research. Read her story in Cancer Today. buff.ly/EBC8SN1

Learn more about Donor-Advised Funds and how you can establish one to support your charitable goals, including advancing lifesaving cancer science and medicine: buff.ly/5Dyq71O #CancerResearchSavesLives

Today is DAF Day, a nationwide celebration of generosity through Donor-Advised Funds. If you have a Donor-Advised Fund, you can give easily and have it counted toward DAF Day's impact by selecting "Donor-Advised Fund" to complete your gift: buff.ly/YHjERhV

Submit an abstract by October 21 for the AACR Special Conference on Cancer Biology-informed Radioligand Therapy (January 7-10; San Diego), chaired by Kayvan Keshari, David Piwnica-Worms, Julie L. Sutcliffe, and David A. Tuveson.
buff.ly/gVPJ8ey
#aacrRLT27

More studies showing the benefits of physical activity for cancer patients and survivors were featured in the AACR #CancerProgressReport 2026, including a reduced risk of secondary primary cancers for childhood cancer survivors and fewer complications from treatment: buff.ly/z2XLMCR

Despite a number of studies showing that exercise can improve cancer outcomes, a recent @nytimes article pointed out that access to exercise programs for patients remains limited: buff.ly/v5VGjGP

Patients with cancer who exercise have been found to have a lower risk of death, reduced risk of recurrence for some cancers, and improved quality of life. Learn more about exercise's benefits for patients on the #AACRBlog: buff.ly/1voCNXq

This approval was based on results from the HER2CLIMB-05 trial, which were presented at the San Antonio Breast Cancer Symposium 2025. Learn more about this trial and the history of tucatinib as a treatment for breast cancer on the AACRBlog: buff.ly/LURJt1a

The @US_FDA approved the HER2 inhibitor tucatinib in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with advanced HER2-positive breast cancer after initial treatment: buff.ly/VeV5WMV

Submit an abstract by November 2 for the AACR Conference on Targeting RAS: Mechanisms, Novel Therapeutics, and Clinical Impact (January 28-31; San Diego), chaired by Ryan B. Corcoran, Julian Downward, Ignacio Garrido-Laguna, and Sandra Misale.
buff.ly/i0N1m1e
#AACRras27 @juliandownward.bsky.social

If you're about to start chemotherapy, you likely have a lot of questions. To help you prepare for your first infusion, Cancer Today asked an oncology nurse what to expect during a typical appointment. Read her response: buff.ly/6ixaM9x

The FDA expanded treatment options for cancers of the breast, lung, pancreas, and more during the third quarter of 2026. Learn how these new approvals fit into the therapeutic landscape on the #AACRBlog: buff.ly/mY5QpZ3

CLL and SLL are the same disease, but in CLL, cells accumulate primarily in the blood and bone marrow, whereas SLL cells concentrate in the lymph nodes. Learn more about this type of blood cancer and treatment options: buff.ly/im5hvpd

The @US_FDA approved the BTK inhibitor pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion: buff.ly/BVGXVtH

The AACR invites professional journalists to submit entries for the 2027 AACR June L. Biedler Prize for Cancer Journalism. The $5,000 prize honors excellence in cancer reporting for the lay public. Learn more: buff.ly/K04idRc